Nicky has a background in biology and a PhD in pharmacology from the University of Greenwich, and more than 30-years’ experience in drug discovery. She has served in a range of lead drug discovery positions, including head of discovery at Sosei Group and Acacia Pharma, CSO at Peptinnovate and VP Drug Discovery Alliances at C4X Discovery. Nicky’s experience and knowhow in drug discovery is key for River BioMedics’ drug discovery strategy and execution.
Marcelo holds a Bachelor’s degree in Biochemistry from Lisbon University, Portugal. In 2008 he moved to the Netherlands, where he completed his Masters in Drug Innovation at Utrecht University. He performed his PhD research at the department of Anatomy and Embryology of the Leiden University Medical Center on hiPSC derived cardiomyocyte maturation and disease modelling, and thereafter held a Postdoc position at the department of Applied Stem Cell Technologies at the University of Twente. Marcelo performed his scientific research with an entrepreneurial spirit and the ultimate goal of societal valorization.
Lisanne has a unique combined background in Medicine and Biomedical Engineering. She obtained her Bachelor’s degree in Medicine at Leiden University, and decided thereafter to make the switch to the Master of Biomaterials & Tissue Biomechanics at Delft University of Technology. Lisanne holds a PhD in Medicine from Leiden University on genetic epidemiology of cardiovascular diseases.
Jiayi obtained a Master’s degree in Molecular Life Science from Wageningen University. During her PhD training at the University Medical Center Utrecht, she focused on acquired and inherited heart diseases and identified several pathomechanisms underlying those diseases. She then took a post-doc position at Netherland Heart Insitute and investigated potential druggable candidates for developing new therapeutic strategies for heart failure patients. Now, Jiayi aims to discover promising (novel) drugs for patients.
Chloë holds a bachelor’s degree in Biology from the Radboud University Nijmegen, specialized in medical and molecular biology. She holds a master’s degree in Molecular Mechanisms of Disease from the Radboud University Nijmegen, focused on studying underlying processes of disease and translating them into treatments for patients. During her internship and employment at the University of Twente in the group of prof. Passier, she worked on maturation of hiPSC-derived cardiomyocytes in a heart-on-chip model. Chloë aims to translate research on heart disease models to effective treatment for patients.
Daphne holds a bachelor’s degree in Biomedical Laboratory Research from Saxion Enschede. Afterwards, she moved to Nijmegen to obtain her master’s degree in Biomedical Sciences from the Radboud University. Through several internships, she has gained a special interest and knowledge in using microfluidic technology for (disease) modelling and drug evaluation. In Nijmegen, she worked on the vascularization of a tumor-on-a-chip model for enhanced evaluation of an anti-cancer adenoviral-mediated IgA therapy. Now, Daphne aims to use improved heart disease models for better drug discovery and development.
Anke has a Master’s degree in Biophysics from the Humboldt University of Berlin and completed her PhD in the BIOS Lab on a chip group at the University of Twente. During her PhD and postdoc she focused on the parallelization and automation of microfluidic cell culture. As part of her work, she contributed to the development of the Translational Organ-on-Chip Platform which uses standardized interfacing of (bio)microfluidic modules to create a ‘plug and play’ system. Anke aims to use microfluidic technology to streamline and optimize the creation and maintenance of heart tissues for disease modeling.
Amélie obtained a bachelor’s degree in digital sciences and biology, and a Master’s degree in Bionanotechnologies, from the JUNIA ISEN Lille engineering school, in France. During her Master’s internship, she worked on a microfluidic label-free method to analyse the viability of boar spermatozoa, in the group of Prof. Albert van den Berg, at the University of Twente. After graduating, Amélie started her PhD by joining River Biomedics and the BIOS lab-on-a-Chip group. She aims to develop a new microfluidic device to maintain heart tissues oxygen and nutrients supply, through flow recirculation automation. This technology will enable high-throughput drug screening for heart disease modeling.
Manuel holds a Bachelor’s degree in Biomedical Engineering from the University of Pisa, with an industrial specialisation. He subsequently obtained a Master’s degree in Biomedical Engineering from the Politecnico di Milano, specialising in cells, tissues, and biotechnology engineering. During his Master’s internship, he worked on a 3D culture model for spinal cord regeneration, focusing on the analysis of a material based on Self-Assembling Peptides. Through this, he acquired knowledge and skills on neural regeneration, 3D cultures techniques and 3D bioprintig. Now, Manuel aims to reproduce cardiac models and tissues to use them as devices for the study of new drugs and therapies.
Clare has over 30 years’ experience in Drug Discovery and Development having worked in the Respiratory and Inflammation, Oncology and Emerging Innovations disease areas in AstraZeneca before joining C4X Discovery. Clare was Senior VP Drug Discovery at C4X Discovery, leading the biology teams and co-managing the research and development pipeline. She played a key role in the out licensing of the Orexin-1 receptor antagonist project to Indivior, and the partnering of the IL-17 inhibitor programme with Sanofi and the Nrf2 activator programme with AstraZeneca.
As Associate Director and Project Leader at AstraZeneca she provided leadership of cross-functional small molecule and biological drug discovery projects and supported development projects up to Phase 2 clinical studies. Clare was also involved in establishing the AstraZeneca Open Innovation platform and in managing academic industry partnerships.
Clare has published more than 20 scientific papers, has a PhD in Neuropharmacology and a first-class Biochemistry degree from the University of Kent, and is a Fellow of the British Pharmacological Society.
Richard is a medicinal chemist with 25 years’ experience in the pharmaceutical industry and is co-founder of two scientific companies. His wide expertise spans numerous therapeutic areas and target classes, with an extensive knowledge of preclinical drug discovery processes and techniques – from hit-to-lead, to lead-optimisation and candidate selection. Richard has contributed to several programmes which have seen small molecules enter the clinic He is an honorary lecturer in medicinal chemistry and pharmaceutical science at several UK universities and is an author on ~30 papers/book chapters/patents, including two Nature review articles. He also has additional interests in bibliometric analyses in medicinal chemistry.
https://www.rgdscience.com/
Simon has over 30 years’ experience at GSK in drug discovery across many therapeutic areas and routes of delivery with a track record for innovation and working cross-discipline and cross-institutions. He has significant expertise in delivering clinical candidates, managing collaborations and in organising and teaching undergraduate courses.
As a Director in Medicinal Chemistry in the Fibrosis Discovery Performance Unit at GSK, Simon led the drug discovery team that delivered multiple integrin clinical candidates. He was one of the most published medicinal chemists in GSK worldwide with over 100 publications including 34 patents (h-index of 30). With a long track record of collaboration, he was the GSK lead for the successful 2019 £12.8m EPSRC Prosperity Partnership grant with the Universities of Nottingham and Strathclyde.
https://www.rgdscience.com/
Ashlee is a Commercial/Business Development advisor with >15 years experience in drug discovery BD (Oxitope Pharma, C4X Discovery, Cancer Research UK, Trans Tasman Commercialisation Fund and Auckland UniServices).
Experience across private and public Biotech supporting fundraising activities and leading the negotiation and execution of pre-clinical out-licensing and multi-asset transactions.
Ashlee holds a Masters in Bioscience Enterprise from the University of Auckland.
Steven holds a Bachelor’s degree in Small Business Management from The Hague University and a Master’s degree in Strategy & Business administration from Amsterdam University, The Netherlands. Steven has over 15 years’ experience in Finance & Accounting in different roles with growing responsibilities in finance and business. He joined River BioMedics in 2022 in the role of finance person. In the last couple of years, he has helped multiple biotech companies to set up and manage their accounting, finance controls and operations systems.